PL3003298T3 - Związki antyfibrogenne, sposoby ich zastosowania - Google Patents

Związki antyfibrogenne, sposoby ich zastosowania

Info

Publication number
PL3003298T3
PL3003298T3 PL14806967.7T PL14806967T PL3003298T3 PL 3003298 T3 PL3003298 T3 PL 3003298T3 PL 14806967 T PL14806967 T PL 14806967T PL 3003298 T3 PL3003298 T3 PL 3003298T3
Authority
PL
Poland
Prior art keywords
methods
fibrogenic
compounds
fibrogenic compounds
Prior art date
Application number
PL14806967.7T
Other languages
English (en)
Inventor
Aziz Ghahary
Yunyuan LI
Ruhangiz T. Kilani
Ryan Hartwell
Original Assignee
The University Of British Columbia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The University Of British Columbia filed Critical The University Of British Columbia
Publication of PL3003298T3 publication Critical patent/PL3003298T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/04Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL14806967.7T 2013-06-05 2014-06-04 Związki antyfibrogenne, sposoby ich zastosowania PL3003298T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361831404P 2013-06-05 2013-06-05
PCT/CA2014/000484 WO2014194407A1 (en) 2013-06-05 2014-06-04 Anti-fibrogenic compounds, methods and uses thereof

Publications (1)

Publication Number Publication Date
PL3003298T3 true PL3003298T3 (pl) 2024-07-15

Family

ID=52007349

Family Applications (1)

Application Number Title Priority Date Filing Date
PL14806967.7T PL3003298T3 (pl) 2013-06-05 2014-06-04 Związki antyfibrogenne, sposoby ich zastosowania

Country Status (14)

Country Link
US (1) US9737523B2 (pl)
EP (1) EP3003298B1 (pl)
JP (1) JP6473938B2 (pl)
KR (1) KR102294405B1 (pl)
AU (1) AU2014277568B2 (pl)
CA (1) CA2914261C (pl)
DK (1) DK3003298T3 (pl)
ES (1) ES2978920T3 (pl)
PH (1) PH12015502717A1 (pl)
PL (1) PL3003298T3 (pl)
RU (1) RU2726416C2 (pl)
SG (1) SG11201510003VA (pl)
WO (1) WO2014194407A1 (pl)
ZA (1) ZA201600015B (pl)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018144461A1 (en) 2017-01-31 2018-08-09 The Board Of Regents Of The University Of Oklahoma Animal wound model and methods of use
CN112168822B (zh) * 2020-09-27 2022-11-08 集美大学 犬尿酸在改善高脂饮食致血脂异常、肥胖、肠道菌群混乱中的用途
CN117529306A (zh) * 2021-05-04 2024-02-06 索维达解决方案有限公司 烟酰胺腺嘌呤二核苷酸(nad)组合物、其制造方法及其使用方法
MX2023013100A (es) * 2021-05-07 2024-01-26 Birchbiomed Inc Quinurenina y derivados de la misma para el tratamiento de cicatrices atroficas.

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI233805B (en) * 1999-07-01 2005-06-11 Fujisawa Pharmaceutical Co Stabilized pharmaceutical composition in lyophilized form as antifungal agent
EP1369114A1 (en) * 2002-06-07 2003-12-10 Peter Priv. Doz. Dr. Terness Use of tryptophan metabolites as pharmaceutical agents
AU2002950217A0 (en) * 2002-07-16 2002-09-12 Prana Biotechnology Limited 8- Hydroxy Quinoline Derivatives
WO2006053390A1 (en) * 2004-11-17 2006-05-26 Angiogen Pharmaceuticals Pty. Ltd. A method of modulating b cell functioning
HUP0700051A2 (en) * 2007-01-17 2008-09-29 Univ Szegedi Use of kynurenic acid and derivatives there of for treating of gastrointestinal disorders associated with enhanced motility and inflammation
US10426765B2 (en) * 2012-06-15 2019-10-01 Conaris Research Institute Ag Pharmaceutical composition containing nicotinic acid and/or nicotinamide and/or tryptophan for positively influencing the intestinal microbiota

Also Published As

Publication number Publication date
JP2016521695A (ja) 2016-07-25
KR20160018676A (ko) 2016-02-17
US20160120857A1 (en) 2016-05-05
ZA201600015B (en) 2019-07-31
EP3003298A1 (en) 2016-04-13
WO2014194407A1 (en) 2014-12-11
BR112015030569A2 (pt) 2017-07-25
AU2014277568B2 (en) 2019-09-19
RU2015156196A (ru) 2017-07-14
NZ715579A (en) 2021-05-28
EP3003298B1 (en) 2024-03-20
ES2978920T3 (es) 2024-09-23
PH12015502717A1 (en) 2016-03-14
AU2014277568A1 (en) 2016-01-28
SG11201510003VA (en) 2016-01-28
JP6473938B2 (ja) 2019-02-27
KR102294405B1 (ko) 2021-08-25
US9737523B2 (en) 2017-08-22
RU2015156196A3 (pl) 2018-05-24
CA2914261C (en) 2020-02-11
DK3003298T3 (da) 2024-06-17
EP3003298A4 (en) 2017-03-22
BR112015030569A8 (pt) 2020-01-07
CA2914261A1 (en) 2014-12-11
RU2726416C2 (ru) 2020-07-14

Similar Documents

Publication Publication Date Title
IL274355B (en) Aza-pyridone compounds and their uses
GB201323008D0 (en) Compounds and uses thereof
GB201317802D0 (en) SmartHaler patent application
GB201312318D0 (en) Novel methods and compounds
EP3012292A4 (en) TREATMENT ADJUVANT, AND COMPOSITION
GB201306980D0 (en) Methods
GB201300707D0 (en) Compounds and processes
HK1223111A1 (zh) 方法
GB201307233D0 (en) Compounds and uses thereof
GB201411896D0 (en) .
GB201312444D0 (en) Methods
ZA201600015B (en) Anti-fibrogenic compounds, methods and uses thereof
GB201308516D0 (en) Methods
GB201309180D0 (en) Compounds and Their Uses
HK1223307A1 (zh) 新型化合物和其用途
GB201314610D0 (en) Compounds and their uses
GB201306248D0 (en) Compounds and their uses
ZA201601880B (en) Hetero-transglycosylase and uses thereof
GB201304234D0 (en) Methods
HK1218781A1 (zh) 方法
GB201323005D0 (en) Compounds and uses thereof
GB201421602D0 (en) Zielfernrohr
GB201312935D0 (en) T,b,s
GB201307201D0 (en) New compounds and uses
GB201307202D0 (en) New compounds and uses